



Appl. No. 10/031,193
Amdt. Dated November 12, 2003
Reply to Office Action of August 12, 2003

Express Mail No. EV 303490085 US
Docket No. NEX86/PCT-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: HICKE ET AL.
SERIAL NO.: 10/031,193
FILED: January 31, 2002
TITLE: TENASCIN-C NUCLEIC ACID
LIGANDS

EXAMINER: BJ Forman
ART UNIT: 1634
CONF. NO: 6209

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Dear Sir:

In a non-final Office Action mailed on August 12, 2003, Claims 1-43 were pending. The Examiner rejected Claims 33-43 under 35 U.S.C. § 112, first paragraph and 35 U.S.C. § 112, second paragraph. The Examiner rejected Claims 1-32 for statutory double patenting, and also rejected claims 33-42 under the judicially created doctrine of obviousness-type double patenting. This Amendment and Response is submitted in response to said Office Action.

Amendments to the Claims are reflected in the Listing of the Claims which begin on page 2 of this paper. Following the entry of this amendment, claim 33 and new claims 44-58 are pending.

Response begins on page 7 of this paper.